Novo Nordisk A/S

Diabetes and Glycaemic Control

Extensive work in type 2 diabetes and type 1 diabetes, with attention to blood glucose control, treatment intensification, and combinations involving basal insulin, GLP-1 receptor agonists, and SGLT2 inhibitors. Research also includes paediatric type 2 diabetes and diabetes-related complications.

  • HbA1c reduction
  • Insulin icodec
  • Oral semaglutide
  • Diabetic retinopathy

Clinical interest extends to metabolic control across age groups, including adolescents and children, with studies touching on diabetes management alongside excess body weight.

Obesity and Weight Management

Focused research in obesity, overweight, and related metabolic risk states, including weight reduction and long-term weight maintenance in adults, adolescents, and children. Trials also cover obesity linked with type 2 diabetes, obstructive sleep apnoea, knee osteoarthritis, and post-menopausal obesity.

  • Cagrilintide
  • CagriSema
  • Semaglutide
  • Liraglutide

Research includes metabolic and appetite-related outcomes in adults and paediatric populations with excess body weight.

Cardiovascular, Renal, and Inflammatory Disease

Work spans heart failure, acute myocardial infarction, atherosclerotic cardiovascular disease, cardiometabolic disease, and chronic kidney disease, often in the setting of systemic inflammation. Studies also include transthyretin amyloid cardiomyopathy and cardiovascular risk reduction.

  • Ziltivekimab
  • ATTR cardiomyopathy
  • Major adverse cardiovascular events
  • Chronic kidney disease progression

Therapeutic interest includes inflammatory pathways in cardiovascular and renal disease, as well as outcomes linked to cardiac function and vascular injury.

Haematology and Blood Disorders

Research activity includes inherited bleeding disorders such as haemophilia A and haemophilia B, with and without factor VIII inhibitors. Studies also address sickle cell disease and thalassaemia.

  • Concizumab
  • Mim8
  • Bleeding prevention
  • Sickle cell disease

The portfolio reflects interest in prophylaxis, bleeding control, and the management of chronic haematologic complications across adult and paediatric populations.

Endocrine, Growth, and Rare Disease Areas

Additional research covers growth hormone deficiency, short stature, Turner syndrome, Noonan syndrome, and small for gestational age children. The sponsor also studies alzheimer’s disease, non-alcoholic steatohepatitis, alcohol-related liver disease, and hereditary haemochromatosis.

  • Somapacitan
  • Paediatric growth disorders
  • NASH
  • Mild cognitive impairment

These programmes include endocrine replacement, liver disease, and neurocognitive conditions, with interest in both common metabolic and less common inherited disorders.

Want to learn more about this study or check if you can participate? Contact us.

Matched clinical trials

  • Evaluation of Ziltivekimab in Patients with Heart Failure with Mildly Reduced or Preserved Ejection Fraction and Systemic Inflammation

    Not recruiting

    3 1 1
    Investigated Diseases:
    Investigated Drugs:
    Bulgaria Czechia France Germany Greece Poland +1
  • Study on the Effects and Safety of Coramitug for Patients with Transthyretin Amyloid Cardiomyopathy (ATTR CM)

    Not recruiting

    2 1
    Investigated Diseases:
    Czechia France Germany Italy The Netherlands Portugal +1
  • Study on How Cagrilintide and Semaglutide Help People with Overweight or Obesity Reduce Weight

    Not recruiting

    3 1
    Belgium Bulgaria Denmark Finland France Germany +4
  • Study on Maintaining Weight Loss in Teens with Obesity Using Semaglutide

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Belgium Denmark France Germany Greece Italy +2
  • Study on the Long-term Weight Loss Effects of Cagrilintide and Semaglutide in Adults with Obesity

    Not recruiting

    3 1
    Investigated Diseases:
    Investigated Drugs:
    Belgium Denmark Portugal
  • Study of NNC0519-0130 and semaglutide in people with chronic kidney disease who are overweight or obese, with or without type 2 diabetes

    Not recruiting

    2 1 1
    Investigated Drugs:
    Bulgaria Italy Poland Spain